14 results about "CC chemokine" patented technology

An immune response may be induced in a subject by administering to the subject a first mRNA construct encoding a homeostatic chemokine, a cytokine, or a fragment thereof, and a second antigen mRNA construct encoding an antigen. The first mRNA construct may encode a homeostatic chemokine, which is a monomeric peptide with a disulfide bridge formed by bonding between two cysteine moieties in the homeostatic chemokine. The homeostatic chemokine may be selected from the group consisting of a CXC chemokine, a CC chemokine, a CX3C chemokine, and a C chemokine. The first mRNA construct may be used as a genetic adjuvant which potentiates an immune response to a target antigen.

A monoclonal antibody is provided which binds to a human CC chemokine receptor 1 (CCR1) and inhibits activation of the human CCR1, or an antibody fragment thereof. The monoclonal antibody binds to an extracellular region of a human CCR1 and inhibits activation of the human CCR1 by a human CC chemokine ligand 15 (CCL15). An antibody fragment thereof, a hybridoma producing the antibody, a nucleic acid having a nucleotide sequence encoding the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment using the hybridoma or the transformant cell; a therapeutic agent and a diagnostic agent containing the antibody or the antibody fragment, and a method for treating and diagnosing a CCR1-related disease using the antibody or the antibody fragment are also provided.

The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from CCR4-IgG1 and recognizes the same epitope. This antibody contains either an IgG4 or a stabilized IgG4 in order to improve binding efficiency and reduce in vivo Fab arm exchange. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer.

The present application relates to the field of biomedical technology, and in particular to an application of a molecular marker combination in radiation pneumonitis; the application includes: using the molecular marker combination as a biomarker for radiation pneumonitis, the molecular marker combination including CXC chemokine ligand 16 and / or CC chemokine ligand 24; by performing cytokine chip detection and screening on peripheral blood specimens of multiple lung cancer patients undergoing chest radiotherapy after radiotherapy, it was found that patients with high expression of CXC chemokine ligand 16 and CC chemokine ligand 24 early after radiotherapy have a higher risk of developing radiation pneumonitis in the future, and therefore the expression levels of CXC chemokine ligand 16 and CC chemokine ligand 24 can be used to make early predictions of the occurrence of radiation pneumonitis, and therefore the above-mentioned molecular marker combination may become an early prediction tool for radiation pneumonitis in clinical practice.

The invention relates to the technical field of molecular biology, and provides a marker combination for diagnosing neonatal necrotizing enterocolitis and application thereof. The marker combination comprises a CC chemokine ligand 20, a heparin binding epidermal growth factor, angiotensin and aldosterone. Four markers related to neonatal necrotizing enterocolitis are obtained through research and screening, whether neonatal necrotizing enterocolitis occurs or not and the severity of neonatal necrotizing enterocolitis can be effectively judged based on the markers, and the markers have high sensitivity and specificity and can be used for detecting neonatal necrotizing enterocolitis. The kit can help clinical diagnosis and prognosis of neonatal necrotizing enterocolitis.

The present invention relates to combination therapies of C-C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors in the treatment of cancer.

The invention relates to a T cell for expressing CAR and a CAR expression vector. Provided is an immune cell (CAR-T cell or the like) having higher antitumor activity than an immune cell (CAR-T cell or the like) that expresses CAR alone (not expressing a cytokine and / or a chemokine). A T cell provided in one aspect of the invention expresses (1) a chimeric antigen receptor (CAR), (2) at least one selected from the group consisting of interleukin-15 (IL-15), interleukin-18 (IL-18), interleukin-21 (IL-21), and interleukin-27 (IL-27), and (3) a CC chemokine ligand 19 (CCL19).

The present disclosure relates to compositions comprising N-substituted-dioxocyclobutenylamino-3-hydroxy-picoliamide compounds or a pharmaceutically acceptable salt or hydrate thereof, methods of preparing said compositions, and uses thereof. The compositions may be useful in the treatment of conditions ameliorated by inhibition of CC chemokine receptor 6.

The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from CCR4− IgG1 and recognizes the same epitope. This antibody contains either an IgG4 or a stabilized IgG4 in order to improve binding efficiency and reduce in vivo Fab aim exchange. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of a cancer.

The invention discloses application of a CC chemokine receptor 7 inhibitor in preparation of a medicine for treating cardiac hypertrophy. The CC type chemokine receptor 7 (chemokine (C-C motif) ligand 7, CCL7) inhibitor comprises a reagent which can be used for inhibiting the expression of a CCL7 gene at the transcription or translation level of the CCL7 gene. Preferably, the CC chemokine receptor 7 inhibitor comprises siRNA (small interfering Ribonucleic Acid), shRNA (short hairpin Ribonucleic Acid), a carrier or a virus containing the siRNA / shRNA, and an antibody of CCL7. According to the application disclosed by the invention, a new function of the CCL7 is found, that is, the CCL7 has an effect of worsening myocardial hypertrophy; the invention further provides application of the CC chemokine receptor 7 as a drug target in screening of drugs for preventing, relieving and / or treating cardiac hypertrophy and application of a CCL7 inhibitor in preparation of drugs for preventing, relieving and / or treating cardiac hypertrophy. The invention provides a new technical means for preventing, relieving and / or treating cardiac hypertrophy.

The present invention discloses a kit for non-invasive diagnosis of type 2 chronic rhinosinusitis with nasal polyps. One technical solution protected by the present invention is the application of a system for detecting the content of inflammatory factors in the preparation of a product for diagnosing or assisting in diagnosing whether a patient with chronic rhinosinusitis with nasal polyps is a patient with type 2 chronic rhinosinusitis with nasal polyps. The inflammatory factors may be interleukin-5, CC chemokine ligand 5 and CC chemokine ligand 26, or interleukin-5, CC chemokine ligand 5, CC chemokine ligand 24, CC chemokine ligand 26 and periostin. The diagnostic AUC of the kit and device for non-invasive rapid diagnosis of type 2 CRSwNP before treatment provided by the present invention is 0.862 or 0.856, both of which are higher than the current clinical indicators for diagnosing type 2 CRSwNP, and can provide a basis for selecting the correct treatment plan, reasonable drugs, biological agents or surgical methods for treating refractory CRSwNP clinically.

This invention relates to N-substituted dioxocyclobutenylamino-3-hydroxypyridine carboxamide compounds of formulas (IIA) and (IIB) that inhibit CC chemokine receptor 6 (CCR6), or pharmaceutically acceptable salts thereof; pharmaceutical compositions containing these compounds; and the use of these compounds for the treatment or prevention of diseases, conditions, or ailments that are improved by inhibiting CCR6.